TGFBR2 KO CAR27/IL-15 NK cells therapy (The University Of Texas MD Anderson Cancer Center)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameTGFBR2 KO CAR27/IL-15 NK cells therapy (The University Of Texas MD Anderson Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionNatural killer cell replacementsAnti-Trop-2
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsLymphatic DiseasesPancreatic NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphatic DiseasesPancreatic NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A